GUFICBIO vs ORCHPHARMA: Stock Comparison

Gufic Biosciences Limited vs Orchid Pharma Limited

Live data: 22 July 2026, 3:05 PM IST • Source: NSE and company filings

Orchid Pharma Limited is the larger company by market capitalisation. Gufic Biosciences Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Orchid Pharma Limited shows lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Gufic Biosciences Limited and Orchid Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, GUFICBIO is more favourable on 11 of 13 scored metrics and ORCHPHARMA on 2These counts are context-free and are not an overall rating.

Key Differences

Market Cap
ORCHPHARMA is the larger company
₹5,072 Cr vs ₹3,846 Cr
P/E Ratio
GUFICBIO has a lower P/E
62.05x vs 253.09x
P/B Ratio
ORCHPHARMA has a lower P/B
4.04x vs 5.99x
EPS
GUFICBIO has higher earnings per share
₹6.42 vs ₹4.01
Dividend Yield
GUFICBIO has a higher dividend yield
0.03% vs 0%
Revenue Growth (TTM YoY)
GUFICBIO has faster revenue growth
22.8% vs -1.5%
EPS Growth (TTM YoY)
GUFICBIO has faster EPS growth
183.1% vs 0%
Qtr Sales Growth
GUFICBIO has stronger quarterly sales growth
22.8% vs 0.05%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricGUFICBIOORCHPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricGUFICBIOORCHPHARMA
Live Price₹386₹1,000.7
Day Change-2.7%-2.18%
Volume43,76883,491
52-Week High₹448₹1,119.8
52-Week Low₹268₹480
Distance from 52W High-13.84%-10.64%

Valuation

MetricGUFICBIOORCHPHARMA
Market Cap₹3,846 Cr₹5,072 Cr
P/E Ratio62.05x253.09x
P/B Ratio5.99x4.04x
EPS₹6.42₹4.01
Book Value₹66.2₹253.98
Dividend Yield0.03%0%

Growth

MetricGUFICBIOORCHPHARMA
Revenue Growth (TTM YoY)22.8%-1.5%
EPS Growth (TTM YoY)183.1%0%
Qtr Sales Growth22.8%0.05%
Qtr Profit Growth184%4.26%

Profitability & Leverage

MetricGUFICBIOORCHPHARMA
ROE10.1%2.12%
ROCE12.3%2.64%
Net Margin6.8%2.51%
Operating Margin16%5.07%
Debt to Equity0.61x0.28x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricGUFICBIOORCHPHARMA
Promoter Holding72.5%69.84%
FII Holding0.42% 0.02 pp0.87% 0.3 pp
DII Holding3.83% 0.09 pp20.25% 0.86 pp
Public Holding23.24% 0.08 pp9.05% 0.55 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Gufic Biosciences Limited and Orchid Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.